Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Limited announced that its Nomination and Remuneration Committee approved the allotment of 11,400 equity shares to eligible employees under the Emcure - Employee Stock Option Scheme 2013, following the exercise of 11,400 vested options. The allotment increases the company’s issued and paid-up share capital from 18,96,99,247 equity shares to 18,97,10,647 equity shares, with an aggregate value increasing from Rs 1,89,69,92,470 to Rs 1,89,71,06,470.

Emcure Pharmaceuticals Ltd. announced reaffirmations from CARE Ratings Limited and CARE Ratings Ltd. regarding several instruments, including Long-term bank facilities totaling Rs 785.00, Long-term/Short-term bank facilities amounting to Rs 1,563.00, and Short-term bank facilities of Rs 52.00, all carrying ratings of CARE AA; Stable and CARE A1+ respectively, with enhancements to the amounts from Rs 557.50 and Rs 1,348.00 previously; additionally, CARE Ratings Limited (CareEdge Ratings) noted potential for a positive rating upgrade if total operating income and PBILDT margins exceed 22%, while a downgrade could occur if net debt to PBILDT rises above 1.50x or PBILDT margins fall below 15%, alongside the withdrawal of ratings for Non-convertible debentures LT as of January 5, 2024, and the completion of the acquisition of a stake in Gennova Biopharmaceuticals Limited for approximately Rs 232 crore in July 2026, alongside a divestment of its mRNA business for roughly Rs 140 crore.

Emcure Pharmaceuticals Limited announced on August 25, 2026, that its Nomination and Remuneration Committee approved the allotment of 19,100 equity shares to eligible employees under the Emcure Employee Stock Option Scheme 2013, following the exercise of vested options. The allotment increased the company’s issued and paid-up share capital from 18,96,80,147 equity shares aggregating to Rs 1,89,68,01,470 to 18,96,99,247 equity shares aggregating to Rs 1,89,69,92,470.

Emcure Pharmaceuticals Limited announced that Berjis Desai will step down as Chairman and Director due to his appointment to the National Commission for Minorities, effective after the company's Annual General Meeting. Simultaneously, the company appointed Raghu Kumar as an Additional Director (Non-Executive and Independent), effective August 6, 2026, and named Satish Mehta, currently Managing Director & CEO, as the new Chairman, also effective after the AGM.

Emcure Pharmaceuticals Limited will hold its 45th Annual General Meeting on September 21, 2026, to approve a final dividend of Rs 3.60 per equity share, representing 36%, for the financial year ended March 31, 2026, with a record date of September 4, 2026.

Emcure Pharmaceuticals Ltd share price slipped 0.91% to Rs 1959.1. The Company's net profit saw a strong growth of 20% to Rs 292.49 crore, while revenue from operations slightly gained 4.48% to Rs 2580.45 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.84 lakh crore, easing 5.15%. It has inched up 1.03% over last one week and advanced by 11.63% in last one month while the market capitalization of Emcure Pharmaceuticals Ltd has improved by 2.57% and 19.40% in the same period respectively. Profit before tax (PBT) of Emcure Pharmaceuticals Ltd stood at Rs 393.53 crore in Q2 FY26, jumping 35.35% year-on-year, and rallying 15.34% quarter-on-quarter. EBITDA came in at Rs 530 crore, expanding by 28.41% YoY and rising by 11.54% sequentially. Total expenses grew marginally by 2.91% to Rs 2157.46 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 481.14 crore, rising 14.95% YoY, while employee benefits expense was at Rs 409.5 crore, inching up 5.87% YoY. For the TTM ended FY26, revenue from operations grew 18.59% to Rs 7896.0 crore, while net profit jumped 34.10% to Rs 707.47 crore, compared to previous TTM. EBITDA surged by 124346% to Rs 1407.12 crore, and PBT witnessed a strong rise of 33.57% to Rs 971.35 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 851.71 crore in FY26, as against Rs 1097.24 crore in FY25. Emcure Pharmaceuticals Ltd rallied 36.57% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.64% during the same period.

Emcure Pharmaceuticals announced that it has completed the acquisition of 663,865 equity shares constituting 12.05% of balance equity share capital of Gennova Biopharmaceuticals (Gennova) for an aggregate consideration of Rs231.87 crore. With this acquisition, Gennova has become a wholly owned subsidiary of the company.

Emcure Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 6 August 2026.

For FY2025-26, the revenue and the networth of the mRNA business of Gennova Biopharmaceuticals were Rs 64.71 crore (0.71% of consolidated revenue of Emcure Pharma) and Rs 132.63 crore (2.68% of consolidated net worth of Emcure Pharma), respectively. The mRNA business business has been divested for a total cash consideration of Rs 139.5 crore. Emcure Pharma expects the transaction to be completed by 17 July 2026. The company stated that the transfer of mRNA business is part of Gennova's strategic initiative to reorganize its business operations and focus on core areas, which are research and development, manufacturing and marketing of biotechnology-based products including biosimilars and adjacent therapeutic platforms. Pune-based Emcure Pharmaceuticals develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Emcure is present in 70+ countries globally, including Europe and Canada. On a consolidated basis, Emcure Pharmaceuticals' net profit rose 28.81% to Rs 243.40 crore while net sales rose 16.70% to Rs 2469.70 crore in Q4 March 2026 over Q4 March 2025. The scrip rose 0.15% to end at Rs 1810.45 on the BSE on Friday. Powered by Capital Market - Live

Gennova Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals, has executed a Business Transfer Agreement for transfer of its mRNA business as a going concern on a slump sale basis for a cash consideration of Rs 139.5 crore to Immunoscript Life Science on 10 July'2026. The transfer of mRNA business is part of Gennova's strategic initiative to reorganize its business operations and focus on core areas - research and development, manufacturing and marketing of biotechnology based products including biosimilars and adjacent therapeutic platforms.